Studies on the antigenicity of an inactivated, aluminum hydroxide adjuvant equine influenza vaccine.

The research article investigates the reaction of horses and guinea pigs to different dosages of a equine influenza vaccine with an aim to determine which quantity would induce the optimum serological response. The goal was to compare the vaccine’s effects in horses (the intended recipient) to the effects in guinea pigs, a commonly used species in laboratory testing.

Research Methodology

• The study used a deactivated equine influenza vaccine with an aluminum hydroxide adjuvant. The aluminum hydroxide component is designed to enhance the immune response to the vaccine.
• The vaccine contained incremental doses of A/Equi-1/Prague and A/Equi-2/Miami strains of equine influenza virus. The doses were doubled each time.
• Different groups of horses and guinea pigs were administered different doses of the vaccine.
• Following the vaccinations, scientists measured the hemagglutination inhibition antibody response. Hemagglutination is a process that causes red blood cells to clump together, and the ‘inhibition’ part refers to the antibody’s ability to prevent this clumping. Measuring this response can indicate the degree of an animal’s immunity to a particular virus.

Outcomes of the Study

• The response to the vaccine varied based on the dose, with some producing a higher average hemagglutination inhibition antibody response. The optimal responses occurred with 128 or 256 hemagglutination units of A/Equi-1 event and 512 or 1024 units of A/Equi-2 event.
• Further increases in the vaccine dosage did not produce higher response levels. In fact, the average hemagglutination inhibition titles were slightly lower than the maximum achieved levels.
• Guinea pigs that were given varying dosages of the vaccine displayed similar responses to the horses. Their antibody titers reached a plateau corresponding with the peak responses observed in the horses.
• Importantly, no negative effects from the vaccinations were observed. The horses remained free of equine influenza symptoms in the year following the test and no post-vaccination reactions were reported.

Implications of the Research

• The results of this study support the use of guinea pigs as a proxy for horses in laboratory tests. The comparable response levels in both species mean that researchers can conduct initial potency tests in the guinea pigs before progressing to full-scale clinical tests in horses.
• Additionally, the research provides valuable data for deciding the optimal dosage levels for this equine influenza vaccine. This can help ensure the vaccines are used efficiently and effectively, leading to better health outcomes for horses.